ACHL

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

Dollar change +0.01
Percentage change 0.86	%

Peers: BNTX CRSP MRNA BEAM PSTX FATE ADPT IKT DTIL

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.66	Insider Own	7.66%	Shs Outstand	41.10M	Perf Week	0.86%
Market Cap	48.09M	Forward P/E	-	EPS next Y	-0.12	Insider Trans	0.00%	Shs Float	37.95M	Perf Month	14.71%
Income	-67.25M	PEG	-	EPS next Q	-0.36	Inst Own	51.57%	Short Float	0.32%	Perf Quarter	18.34%
Sales	0.00M	P/S	-	EPS this Y	89.66%	Inst Trans	46.72%	Short Ratio	0.71	Perf Half Y	39.47%
Book/sh	2.51	P/B	0.47	EPS next Y	33.33%	ROA	-45.13%	Short Interest	0.12M	Perf Year	28.81%
Cash/sh	2.09	P/C	0.56	EPS next 5Y	-	ROE	-52.41%	52W Range	0.63 - 1.76	Perf YTD	2.63%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-65.21%	52W High	-33.52%	Beta	1.30
Dividend TTM	-	Quick Ratio	6.04	Sales past 5Y	0.00%	Gross Margin	-	52W Low	85.71%	ATR (14)	0.05
Dividend Ex-Date	-	Current Ratio	6.04	EPS Y/Y TTM	3.33%	Oper. Margin	-	RSI (14)	63.58	Volatility	3.84% 5.06%
Employees	215	Debt/Eq	0.04	Sales Y/Y TTM	-	Profit Margin	-	Recom	4.00	Target Price	0.50
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	-18.29%	Payout	-	Rel Volume	0.30	Prev Close	1.16
Sales Surprise	-	EPS Surprise	-17.07%	Sales Q/Q	-	Earnings	Nov 14 BMO	Avg Volume	171.11K	Price	1.17
SMA20	6.63%	SMA50	9.68%	SMA200	27.75%	Trades		Volume	51,952	Change	0.86%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-05-24	Downgrade	Piper Sandler	Overweight → Neutral	$8 → $2
Apr-26-21	Initiated	Piper Sandler	Overweight	$25
Apr-26-21	Initiated	Oppenheimer	Outperform	$23
Apr-26-21	Initiated	JP Morgan	Underweight	$11
Apr-26-21	Initiated	Chardan Capital Markets	Buy	$27
Apr-26-21	Initiated	BofA Securities	Buy	$20

Dec-25-24 09:35AM	Achilles Therapeutics sells technology assets to AstraZeneca for $12M (TipRanks)
Dec-24-24 09:30AM	Achilles Therapeutics Announces Sale of Technology Assets to AstraZeneca (GlobeNewswire) +16.18%
Nov-19-24 07:00AM	Achilles Therapeutics Receives Approval to Transfer to Nasdaq Capital Market (GlobeNewswire)
Nov-14-24 07:00AM	Achilles Therapeutics Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Sep-23-24 09:40AM	Is Achilles Therapeutics (ACHL) Stock Outpacing Its Medical Peers This Year? (Zacks) -6.19%
07:00AM	Loading…
Sep-19-24 07:00AM	Achilles Therapeutics Announces Strategic Update (GlobeNewswire) +32.39%
Aug-14-24 07:00AM	Achilles Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Updates (GlobeNewswire)
May-22-24 07:00AM	Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines (GlobeNewswire)
May-17-24 05:00PM	Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement (GlobeNewswire)
May-08-24 01:53PM	ACHL Stock Earnings: Achilles Therapeutics Beats EPS for Q1 2024 (InvestorPlace) +11.25%
07:00AM	Achilles Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Apr-04-24 11:53AM	ACHL Stock Earnings: Achilles Therapeutics Misses EPS for Q4 2023 (InvestorPlace) -24.76%
06:45AM	Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
06:30AM	Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning (GlobeNewswire)
Feb-05-24 07:00AM	Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference (GlobeNewswire)
07:00AM	Loading…
Dec-18-23 07:00AM	Achilles Therapeutics Announces Publication of Nature Cancer 'Comment' on Strategy for Improved Neoantigen Immunogenicity Prediction (GlobeNewswire)
Nov-13-23 04:30PM	Achilles Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights (GlobeNewswire)
Oct-24-23 12:30PM	10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis (ACCESSWIRE)
Sep-22-23 04:30PM	Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement (GlobeNewswire)
09:40AM	Are Medical Stocks Lagging Achilles Therapeutics (ACHL) This Year? (Zacks)
Sep-13-23 12:05PM	Waters (WAT) Walk-Up Solutions Boost Bioprocess Development (Zacks)
Sep-06-23 09:40AM	Is KalVista Pharmaceuticals (KALV) Stock Outpacing Its Medical Peers This Year? (Zacks)
Aug-10-23 11:50AM	Jazz (JAZZ) Beats on Q2 Earnings & Sales, Raises '23 View (Zacks)
Aug-04-23 07:00AM	Achilles Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Jun-12-23 08:00AM	Achilles Therapeutics to Present at Upcoming Conferences (GlobeNewswire)
May-21-23 10:03AM	3 Stocks With 1,000% Upside Potential (InvestorPlace)
May-10-23 07:15AM	Achilles Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
07:00AM	Achilles Therapeutics New Immunogenicity Prediction Application of its AI-Powered PELEUS Platform Uniquely Identifies the Most Potent T Cell Antigens (GlobeNewswire)
Apr-25-23 06:00PM	Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement (GlobeNewswire)
07:00AM	Achilles Therapeutics Announces Grant of US Patent Covering the Treatment of Patients with an Immunotherapy Targeting Neoantigens Based on Tumor HLA Status (GlobeNewswire)
09:45AM	Loading…
Apr-22-23 09:45AM	Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Apr-17-23 08:00AM	Achilles Therapeutics to Present at Chardans 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit (GlobeNewswire)
Mar-07-23 07:00AM	Achilles Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Business Highlights (GlobeNewswire)
Feb-02-23 09:40AM	Is Achilles Therapeutics (ACHL) Outperforming Other Medical Stocks This Year? (Zacks)
Jan-17-23 09:40AM	Is Anika Therapeutics (ANIK) Stock Outpacing Its Medical Peers This Year? (Zacks)
Dec-20-22 08:30AM	Achilles Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-06-22 06:00AM	Achilles Therapeutics Presents Encouraging Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma at ESMO IO Congress 2022 (GlobeNewswire) -12.28%
Nov-30-22 06:05PM	Achilles Therapeutics to Present Early Proof of Concept of Safety and Clinical Activity of Clonal Neoantigen Reactive T Cells at the ESMO Immuno-Oncology Annual Congress 2022 (GlobeNewswire) +6.32% -13.37%
Nov-22-22 08:00AM	Achilles Therapeutics Announces Grant of US Patent on Immunotherapies Targeting Clonal Neoantigens Identified Using Proprietary Method (GlobeNewswire)
Nov-13-22 07:48AM	Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Nov-08-22 07:00AM	Achilles Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights (GlobeNewswire) -10.05%
Nov-01-22 12:00PM	What Makes Achilles Therapeutics PLC Sponsored ADR (ACHL) a New Buy Stock (Zacks)
Oct-06-22 08:30AM	Achilles Therapeutics Co-founder Professor Charles Swanton to Participate in Expert Roundtable Highlighting Pivotal Nature of Neoantigens as Targets in Cancer Cell Therapy (GlobeNewswire)
Sep-07-22 01:15PM	Gilead's (GILD) Tecartus Gets EC Nod for New Cancer Indication (Zacks)
Aug-31-22 12:53PM	Curis (CRIS) Gets FDA Nod to Partly Resume Leukemia Study (Zacks)
Aug-26-22 01:34PM	Kodiak Sciences (KOD) Rises 60% in Past 3 Months: Here's Why (Zacks)
Aug-25-22 11:53AM	AstraZeneca (AZN) Gets Japan Nod for Expanded Use of 3 Drugs (Zacks)
Aug-24-22 01:33PM	Amgen (AMGN) Posts Positive Data from Soliris' Biosimilar Study (Zacks)
Aug-23-22 01:53PM	Horizon (HZNP) Marketed Drugs Aid Growth, Stiff Rivalry a Woe (Zacks)
Aug-19-22 12:32PM	Kodiak Sciences (KOD) Focuses on Developing Eye Drug Tarcocimab (Zacks) -7.76%
Aug-16-22 10:09AM	Horizon (HZNP) Inks Collaboration Deal with Q32 Bio for ADX-914 (Zacks)
Aug-09-22 07:00AM	Achilles Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights (GlobeNewswire)
Aug-01-22 06:00AM	What Is The Ownership Structure Like For Achilles Therapeutics plc (NASDAQ:ACHL)? (Simply Wall St.)
Jul-21-22 08:00AM	Achilles Therapeutics to lead Horizon Europe-Funded Consortium to Advance Personalized Cell Therapy Manufacturing (GlobeNewswire)
Jun-30-22 08:00AM	Achilles Therapeutics Appoints James Taylor as Chief Business Officer and Cassian Yee, MD to Scientific Advisory Board (GlobeNewswire)
Jun-21-22 08:30AM	Achilles Therapeutics Recognized with the 2022 PING Innovation Award (GlobeNewswire)
Jun-06-22 08:40AM	Here's Why We're Watching Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation (Simply Wall St.)
May-10-22 07:00AM	Achilles Therapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights (GlobeNewswire) +5.10%
May-09-22 07:00AM	Achilles Therapeutics Doses First Patient with Higher-dose cNeT in Phase I/IIa CHIRON Trial in Advanced NSCLC and Initiates Enrollment in Cohort B of the THETIS Trial (cNeT + PD-1 checkpoint inhibitor) in Metastatic Malignant Melanoma (GlobeNewswire) -9.26%
May-04-22 08:00AM	Achilles Therapeutics Appoints Bernhard Ehmer to Board of Directors (GlobeNewswire)
May-03-22 08:00AM	Achilles Therapeutics to Present at Upcoming Conferences (GlobeNewswire) +7.24%
Apr-14-22 11:27AM	Center for Breakthrough Medicines' latest deal is with London biotech firm Achilles Therapeutics (American City Business Journals) -7.78%
Apr-12-22 07:30AM	The Center for Breakthrough Medicines (CBM) Strikes Multi-Year Deal with UK Cell Therapy Powerhouse (PR Newswire) -10.39%
07:30AM	Achilles Therapeutics Announces Manufacturing Expansion in the UK and Partnership for Manufacturing in the US (GlobeNewswire)
Apr-05-22 08:00AM	Achilles Therapeutics to Present at Upcoming Conferences (GlobeNewswire) -7.57%
Apr-04-22 08:00AM	Achilles Therapeutics to Host KOL Webcast to Highlight TRACERx Study Presentations from the 2022 AACR Annual Meeting (GlobeNewswire)
Mar-08-22 08:00AM	Achilles Therapeutics to Present at the 32nd Annual Oppenheimer Healthcare Conference (GlobeNewswire)
Mar-01-22 09:00AM	Achilles Therapeutics Selects Netralitys 401 North Broad for United States Headquarters (GlobeNewswire) -7.25%
07:02AM	Achilles Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Recent Business Highlights (GlobeNewswire)
04:00AM	London-based Achilles Therapeutics picks Philadelphia for its first U.S. location (American City Business Journals)
Feb-07-22 07:30AM	Achilles Therapeutics Strengthens Scientific Advisory Board with Appointment of Alena Gros, Ph.D. and Ben Creelan, M.D. (GlobeNewswire)
Jan-13-22 07:30AM	Achilles Therapeutics Provides Business Update and Outlook for 2022 (GlobeNewswire) -6.03%
Dec-28-21 04:09AM	Achilles Therapeutics (NASDAQ:ACHL) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Dec-21-21 08:00AM	Achilles Therapeutics to present at the 40th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +6.65%
Dec-20-21 08:00AM	Achilles Therapeutics Added to the NASDAQ Biotechnology Index (GlobeNewswire)
Dec-09-21 07:00AM	Achilles Therapeutics Presents Positive Data at ESMO I-O Congress 2021 on High-Dose Manufacturing Process for Precision T Cell Therapies Targeting Clonal Neoantigens (GlobeNewswire) -6.58%
Nov-12-21 07:00AM	Achilles Therapeutics Presents Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting Demonstrating the Ability to Detect, Quantify and Track Patient-specific cNeT and Significant Increase in cNeT Dose from VELOS Process 2 Manufacturing (GlobeNewswire) -5.07%
Nov-10-21 08:15AM	Secarna Pharmaceuticals and Achilles Therapeutics Sign Research, Option and License Agreement to Develop Optimized T Cell Therapies (ACCESSWIRE)
Nov-09-21 08:00AM	Achilles Therapeutics Reports Third Quarter 2021 Financial Results and Recent Business Highlights (GlobeNewswire)
Oct-22-21 07:30AM	Achilles Therapeutics Presents Data at the 2021 European Society for Gene and Cell Therapy (ESGCT) Congress Demonstrating its Proprietary Manufacturing Process Can Generate Potent, Personalized Anti-Cancer Cell Therapy Candidates in Multiple Solid Tumor Types (GlobeNewswire) -8.61%
Oct-12-21 08:00AM	Achilles Therapeutics to join the Northern Alliance Advanced Therapy Treatment Centre consortium (GlobeNewswire) +7.00%
Oct-01-21 08:00AM	Achilles Therapeutics to Present at Upcoming Scientific Congresses (GlobeNewswire)
Sep-29-21 06:15AM	Here's What Achilles Therapeutics plc's (NASDAQ:ACHL) Shareholder Ownership Structure Looks Like (Simply Wall St.) -5.04%
Sep-02-21 08:30AM	Achilles Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-25-21 08:00AM	Achilles Therapeutics Announces Grant of US and European Patents (GlobeNewswire)
Aug-10-21 07:00AM	Achilles Therapeutics Reports Second Quarter 2021 Financial Results and Recent Business Highlights (GlobeNewswire) +22.13%
Jul-26-21 03:00PM	Is Achilles Therapeutics plc (ACHL) A Good Stock To Buy? (Insider Monkey)
Jul-01-21 08:00AM	Achilles Therapeutics Enrolls First US Patient in Ongoing Phase I/IIa Study in Advanced Non-small Cell Lung Cancer (GlobeNewswire)
04:40AM	We Think Achilles Therapeutics (NASDAQ:ACHL) Can Afford To Drive Business Growth (Simply Wall St.)
Jun-04-21 09:00AM	Achilles Therapeutics Details Phase I/IIa Clinical Trial Design of CHIRON in Patients with Advanced Non-Small Cell Lung Cancer at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
May-11-21 07:00AM	Achilles Therapeutics Reports First Quarter 2021 Financial Results and Recent Business Highlights (GlobeNewswire)
May-06-21 08:00AM	Achilles Therapeutics Receives Horizon 2020 Grant as Part of Neoantigen Consortium (GlobeNewswire) -10.07%
May-05-21 08:30AM	Achilles Therapeutics to present at the BofA Securities 2021 Virtual Healthcare Conference (GlobeNewswire)
May-03-21 08:00AM	Achilles Therapeutics Appoints Julie ONeill to Board of Directors and Markwin Velders, Ph.D. joins Scientific Advisory Board (GlobeNewswire)
Apr-10-21 08:30AM	Achilles Therapeutics Demonstrates cNeT Product Characterization and Post-Infusion Tracking in a Patient Case Study at the American Association for Cancer Research (AACR) 2021 Annual Meeting (GlobeNewswire)
Apr-06-21 04:01PM	Achilles Therapeutics Announces Closing of $175.5 million Initial Public Offering (GlobeNewswire) +19.71% -12.60%
Mar-31-21 02:01PM	Two Companies Went Public Today. One Climbed, the Other Dropped. (Barrons.com)
Mar-30-21 07:00PM	Achilles Therapeutics Announces Pricing of Initial Public Offering (GlobeNewswire)

Achilles Therapeutics Plc is a biopharmaceutical company engaged in developing transformative precision T-cell therapies to treat multiple types of solid tumors. It focuses on researching, developing and commercializing potentially novel cancer immunotherapies targeting clonal neoantigens. The company was founded by Karl Peggs, Sergio Quezada, Mark Lowdell and Charles Swanton in November 2020 and is headquartered in London, the United Kingdom.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Achilles Therapeutics Plc ADR

Upgrade your FINVIZ experience